ChemicalBook
Chinese Japanese Germany

Orlistat

Indications and Usage Mechanism of Action Pharmacokinetics Drug Interactions Side Effects Warnings and Precautions
Orlistat
Orlistat
CAS No.
96829-58-2
Chemical Name:
Orlistat
Synonyms
XENICAL;oristat;Olistat;ORLISTAT;HY-B0218;Orlistate;Orlipastat;RO-18-0647;ORLIPASTATUM;Ro 18-0647/002
CBNumber:
CB2431985
Molecular Formula:
C29H53NO5
Formula Weight:
495.73
MOL File:
96829-58-2.mol

Orlistat Properties

Melting point:
<50 °C
alpha 
D20 -32.0° (c = 1 in chloroform)
storage temp. 
2-8°C
solubility 
DMSO: 19 mg/mL
form 
solid
color 
white
InChIKey
AHLBNYSZXLDEJQ-FWEHEUNISA-N
CAS DataBase Reference
96829-58-2(CAS DataBase Reference)

SAFETY

WGK Germany  3
RTECS  OH3167600
Hazardous Substances Data 96829-58-2(Hazardous Substances Data)

Orlistat price More Price(7)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 1478800 Orlistat United States Pharmacopeia (USP) Reference Standard 96829-58-2 200mg $775 2017-11-08 Buy
Sigma-Aldrich O4139 Orlistat ≥98%, solid 96829-58-2 25mg $118 2017-11-08 Buy
Alfa Aesar J62999 Orlistat, 98% 96829-58-2 50mg $67.4 2017-11-08 Buy
Alfa Aesar J62999 Orlistat, 98% 96829-58-2 100mg $127 2017-11-08 Buy
Sigma-Aldrich PHR1445 Orlistat Pharmaceutical Secondary Standard; Certified Reference Material 96829-58-2 1g $103.5 2017-11-08 Buy

Orlistat Chemical Properties,Uses,Production

Indications and Usage

Orlistat is an internationally recognized new form of weight loss drug. Its commercial name is Sainike and first went on sale in New Zealand in 1998. Orlistat is a long-term and highly effective specific gastrointestinal lipase inhibitor, and it is insoluble in water, soluble in chloroform, and easily soluble in ethanol.
Orlistat can be used clinically to treat obesity. Usually, a dose of 120mg is taken three times a day within one hour of a meal. Weight loss begins to occur after two weeks of usage. It can be used continuously for 6-12 months, and its effects will cease to increase after daily dosage exceeds 400mg. This drug is suitable to be used in combination with a low-calorie diet by obese and overweight individuals, and it can also be used as long-term treatment for patients who have faced weight-related risk factors. Orlistat has a long-term weight-control effect that reduces and maintains weight and prevents against rebounding. Using Orlistat can lower the occurrences of weight-related risk factors and diseases, including hypercholesterolemia, type-2 diabetes, impaired glucose tolerance, hyperinsulinemia, and hypertension, and it can reduce the fat content in organs. Orlistat also adjusts blood lipid levels: it can decrease serum triglycerides (TG) and low density lipoprotein cholesterol (LDL-C), and it can increase the ratio of high density lipoproteins to low density lipoproteins in obese patients.

Mechanism of Action

Orlistat is a type of lipase inhibiting weight loss drug and is a hydrated derivative of lipostatin. Orlistat effectively and selectively inhibits stomach lipase and pancreatic lipase, while having no impact on other digestive enzymes (such as amylase, trypsin and chymotrypsin) and on phospholipase, nor does it affect the absorption of carbohydrates, protein and phospholipids. This drug is not absorbed though the gastrointestinal tract and has a reversible inhibiting effect on lipase. Orlistat deactivates enzymes by covalent binding to the serine residue on the active sites of stomach and pancreatic lipase. This prevents the fat in food from being broken down into free fatty acids and diacylglycerol, so it cannot be absorbed, lowering caloric intake and therefore controlling body weight. This drug does not need to be absorbed by the entire body to take effect. Orlistat’s pharmacological activity is dose dependent: a treatment dosage of Orlistat (120mg/d, tid, taken with meals), combined with a low-calorie diet, can reduce up to 30% of fat absorption. In a study comparing normal and obese volunteers, Orlistat was basically not absorbed by the body at all and had a very low blood concentration. After a single oral dosage (the largest being 800mg), the blood concentration of Orlistat in the following 8 hours was <5 ng/ml. Typically, a treatment dosage of Orlistat is only minimally absorbed by the body and will not accumulate in a short treatment period. In an in vitro experiment, Orlistat’s binding rate with other serum proteins exceeded 99% (bound proteins were mainly lipoproteins and albumin), and its binding rate with red blood cells was very low.

Pharmacokinetics

Minimal absorption when ingested orally, can be metabolized and deactivated in the intestinal tract, metabolizing area is the stomach wall, clearing half-life is about 14-19 hours. A study of obese patients showed that the essentially unabsorbed Orlistat produced two main metabolites in blood: M1(4 lactone ring hydrolysate) and M3 (M1 adhered to an N-leucine cleavage product) compose 42% of total blood concentration. M1 and M3 have extremely weak inhibiting effects on lipase and can both be excreted through bile. About 97% of the drug is excreted through feces, 83% of which is excreted in its original form. The cumulative renal output of Orlistat and its metabolites is lower than 2%, and the complete excretion of the drug (through feces and urine) requires 3-5 days.

Drug Interactions

May reduce absorption of vitamin A, D and E; take supplements when using this drug. Any preparations containing vitamin A, D or E (such as compound vitamin preparations), should be taken 2 hours after this drug or before bed.
Type-2 diabetes patients may need to decrease dosage of antidiabetic drugs (such as sulfonylurea).
Combined use with cyclosporine may lower the blood concentration of the latter drug.
Combined use with amiodarone may reduce absorption of the latter drug, thus decreasing its curative effects.

Side Effects

There have been rare cases of Orlistat use leading to elevated transaminase, elevated alkaline phosphatase, and severe hepatitis. There have also been cases of liver failure, some of which required liver transplant surgery or led to death. Orlistat has also had rare reports of allergic reactions, mostly including itchiness, rashes, hives, neurovascular edema, bronchospasm and allergic reactions, as well as very rare reports of herpes. Monitoring of sales also found reports of pancreatitis.

Warnings and Precautions

Orlistat has led to rare cases of acute hepatocellular necrosis and acute liver failure, some of which required liver transplants or led to death. Thus, prescribing physicians must inform patients to immediately cease use of Orlistat and other suspicious drugs and seek inspection for liver functions if any symptoms or signs of liver function abnormalities occur (such as reduced appetite, itchiness, jaundice, dark urine, light feces, or pain in the upper right quadrant).

Chemical Properties

Off-White Solid

Uses

An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent.

Uses

antidiabetic

Uses

Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor.

Uses

Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity.

Biological Activity

Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A 2 , liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G 1 /S boundary in vitro . Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo .

Orlistat Preparation Products And Raw materials

Raw materials

Preparation Products


Orlistat Suppliers

Global( 248)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 sales01@cooperate-pharm.com CHINA 457 55
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 sales@capotchem.com China 19953 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3230 55
Nanjing Sunlida Biological Technology Co., Ltd. 025-58378339;025-57798810
025-57019371 sales@sunlidabio.com China 3866 55
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969
020-39119999 isunpharm@qq.com, isunpharm@hotmail.com China 4990 55
XiaoGan ShenYuan ChemPharm co,ltd Tell:86-712-2580635 Mobile:15527768850 . 15527768836
86-712-2580625 QQ:1623551145 sales02@farchem.com China 9208 52
Taizhou DongBang Fine Chemical Co. Ltd. +86-0523-86235448 15996000437
+86-0523-86235448 2535251509@qq.com China 48 55
Wuhan Runzeweiye Technology Co., Ltd. 027-50779735 15172337137 QQ:940329747
027-50779735 runzeweiye999@163.com China 797 55
JINAN SHENGQI PHARMACEUTICAL CO., LTD 0531-88895833 0531-88892016 15069007290
0531-88892171 15069007290@163.com China 195 58
Wuhan Deme Biological Technology Co., Ltd 17192727886
027-50461101 3242502040@qq.com China 83 58

96829-58-2(Orlistat)Related Search:


  • (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER
  • RO-18-0647
  • (-)-TETRAHYDROLIPSTATIN
  • ORLISTAT
  • N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER
  • Enzyme Inhibitors by Enzyme
  • Enzymes, Inhibitors, and Substrates
  • Enzyme Inhibitors
  • XENICAL
  • L to O
  • Lipase, Pancreatic
  • BioChemical
  • Biochemicals and Reagents
  • 96829-58-2
  • (-)-Tetrahydrolipstatin(EquivalentToOrlistat)
  • C29H53NO5
  • Orlipastat
  • Xenical, (-)-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl Ester,
  • Orlistate
  • Pharmaceutical Raw Materials
  • Orlistat, Tetrahydolipstat
  • ORLIPASTATUM
  • Miscellaneous Biochemicals
  • API
  • Antiobesity Agent
  • C25H53NO3
  • Ro 18-0647/002
  • Chiral Reagents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • (-)-Tetrahydrolipstatin, Ro-18-0647, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
  • L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
  • N-Formyl-L-leucine (1S)-1-[[(2S)-3α-hexyl-4-oxooxetan-2β-yl]methyl]dodecyl ester
  • N-Formyl-L-leucine (S)-1-[[(2S)-3α-hexyl-4-oxooxetane-2β-yl]methyl]dodecyl ester
  • Orlistat,()-Tetrahydrolipstatin, N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester, Ro-18-0647
  • Orlistat (200 mg)
  • ORLISTAT (BULK MATERIAL)
  • ORLISTAT PELLETS 50%
  • Amino Acids & Derivatives
  • Heterocycles
  • Orlistat(synthesis)
  • Orlistat(FerMentation)
  • S,S,S,S-Orlistat
  • (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-forMaMido-4-Methylpentanoate
  • oristat
  • ACTOS
  • Orlipastat, Orlistat
  • Other APIs
  • N-formyl-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester L-Leucine
  • Orlistat N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester
  • Lipid-lowering medicine reducing weight
  • Orlistat Powder
  • Orlistat, >=98%
  • Olistat
  • Lipase Inhibitor, THL
  • HY-B0218
Copyright 2017 © ChemicalBook. All rights reserved